The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...

Just weeks after Madhya Pradesh became a grim symbol of state failure with the deaths of more than 20 children due to ...

The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...

FDA approves FUROSCIX® for use in pediatric patients weighing 43kg or aboveUSPTO issues five patents for FUROSCIX ReadyFlow™ AutoinjectorWESTLAKE ...

Marine animals can be fascinating and quite beautiful. However, you should not approach some of them. Certain fish and ...

Here, we discuss three biotech stocks that put up a robust show in 2025 and are likely to maintain the same in 2026 on the back of a solid portfolio and a promising pipeline. These are EyePoint, Inc.

Mepolizumab reduced COPD exacerbations in patients with eosinophilic inflammation, highlighting the potential of ...

A new study found a more than 200% rise in health problems requiring emergency medical attention after the January 2025 fires ...

When temperatures drop and cold and flu season kicks in, many turn to humidifiers to soothe symptoms like sore throats, chapped lips and sinus dryness. Humidifiers also offer relief to those suffering ...

Modified endotracheal tubes designed to reduce patient pneumonia risk failed to improve outcomes compared to standard ...